J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial. The trial was evaluating Tremfya (guselkumab) in moderate to severe plaque psoriasis. Results were presented at the 39th Fall Clinical Dermatology Conference held in Las Vegas, Nevada.